60 Degrees Pharmaceuticals’ (SXTP) “Sell (E+)” Rating Reiterated at Weiss Ratings

Weiss Ratings reissued their sell (e+) rating on shares of 60 Degrees Pharmaceuticals (NASDAQ:SXTP) in a research report report published on Wednesday,Weiss Ratings reports.

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of 60 Degrees Pharmaceuticals in a research report on Friday, January 10th.

60 Degrees Pharmaceuticals Stock Performance

60 Degrees Pharmaceuticals stock opened at $0.45 on Wednesday. 60 Degrees Pharmaceuticals has a fifty-two week low of $0.41 and a fifty-two week high of $7.20. The firm has a 50 day moving average price of $0.95 and a 200 day moving average price of $1.09. The company has a market capitalization of $3.31 million, a PE ratio of -0.04 and a beta of 4.22.

Insider Activity at 60 Degrees Pharmaceuticals

In related news, CEO Geoffrey S. Dow purchased 35,823 shares of 60 Degrees Pharmaceuticals stock in a transaction that occurred on Monday, December 9th. The stock was purchased at an average cost of $1.27 per share, with a total value of $45,495.21. Following the completion of the transaction, the chief executive officer now directly owns 94,580 shares in the company, valued at approximately $120,116.60. The trade was a 60.97 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders purchased a total of 60,372 shares of company stock valued at $76,975 over the last ninety days. Insiders own 10.27% of the company’s stock.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.